Foghorn therapeutics appoints dr. thomas j. lynch, jr. to its board of directors

Cambridge, mass., oct. 27, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of thomas lynch jr., m.d., to its board of directors.
FHTX Ratings Summary
FHTX Quant Ranking